UPDATE: Audentes Therapeutics (BOLD) PT Raised to $38 at Mizuho Securities; 'New AT-132 Data Looks Promising'
Mizuho Securities raised its price target on Audentes Therapeutics (NASDAQ: BOLD) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)